Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
DV1R0X
|
|||
Drug Name |
CC-95775
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C82-C85; ICD-9: 200, 202] | Phase 1 | [1] | |
Company |
Bristol-Myers Squibb
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Bromodomain and extraterminal domain protein (BET) | Target Info | Inhibitor | [2] |
KEGG Pathway | SNARE interactions in vesicular transport | |||
Reactome | COPII (Coat Protein 2) Mediated Vesicle Transport | |||
WikiPathways | miR-targeted genes in squamous cell - TarBase | |||
miR-targeted genes in muscle cell - TarBase | ||||
miR-targeted genes in lymphocytes - TarBase |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT04089527) Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma. U.S. National Institutes of Health. | |||
REF 2 | Clinical pipeline report, company report or official report of Bristol-Myers Squibb. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.